Toxic epidermal necrolysis caused by vemurafenib in a metastatic malignant melanoma

Area of Science:

• Oncology
• Dermatology
• Pharmacology

Background:

• Combination targeted therapy with vemurafenib and cobimetinib is a standard treatment for metastatic melanoma.
• Severe cutaneous adverse reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis (TEN), are known risks.
• The incidence and management of TEN in patients receiving this combination therapy require further understanding.

Purpose of the Study:

• To report a case of life-threatening toxic epidermal necrolysis (TEN) following vemurafenib and cobimetinib treatment for metastatic melanoma.
• To describe the clinical presentation and management of this severe adverse reaction.
• To contribute to the understanding of rare but serious side effects of targeted melanoma therapy.

Main Methods:

• Case report of a patient with metastatic melanoma treated with vemurafenib and cobimetinib.
• Detailed documentation of the development and progression of severe cutaneous adverse reactions.
• Description of the therapeutic interventions and patient recovery process.

Main Results:

• The patient developed a life-threatening episode of toxic epidermal necrolysis (TEN) during combination targeted therapy.
• Despite the severity of the reaction, the patient experienced a prolonged but successful recovery.
• This case underscores the potential for severe dermatological toxicity with this treatment regimen.

Conclusions:

• Vemurafenib and cobimetinib therapy, while effective for metastatic melanoma, carries a risk of severe cutaneous adverse reactions like TEN.
• Prompt recognition and intensive management are crucial for patient survival and recovery from TEN.
• Further research into predicting and mitigating these rare but severe side effects is warranted.